Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorBaran, Yusufen_US
dc.contributor.advisorSaydam, Gürayen_US
dc.contributor.authorKiraz, Yağmur-
dc.identifier.citationKiraz, Y. (2014). Expression levels of JAK/STAT signaling genes in newly diagnosed, drug sensitive and resistant chronic myeloid leukemia patients. Unpublished master's thesis, İzmir Institute of Technology, İzmir, Turkeyen_US
dc.descriptionThesis (Master)--Izmir Institute of Technology, Molecular Biology and Genetics, Izmir, 2014en_US
dc.descriptionIncludes bibliographical references (leaves: 45-58)en_US
dc.descriptionText in English; Abstract: Turkish and Englishen_US
dc.descriptionx, 58 leavesen_US
dc.description.abstractJAK/STAT signaling pathway has a role in transmission of information carried by cytokines, from outside of the cell to the nucleus. The system is run by the proteins known as Janus kinases (JAK) located on the cell membrane and STAT proteins acting as signal transducer and activator of transcription. JAK proteins activated by cytokines, phosphorylates and initiates the dimerization of STATs, which become active, move into nucleus and regulate expression of target genes. Previous studies demonstrated that there is overexpression of JAK/STAT genes in various types of cancer. The aim of this study is to examine the relationship between expression levels of JAK/STAT genes and clinical outcome of chronic myeloid leukemia (CML) patients. In this study expression levels of Jak/STAT pathway genes were analyzed in 23 different patients (1 patient responded positively, 1 only imatinib and 1 both imatinib and nilotinib resistant patients, 1 patient lost molecular response, 5 imatinib treated, and 14 newly diagnosed CML patients). The results showed that expression levels of Jak3, STAT1, STAT2, STAT3, STAT4 and STAT5A genes were overexpressed in TKI resistant patients. Expression levels of STAT5B, Jak1, Jak2 and Tyk2 genes were higher in newly diagnosed patients compared to resistant patients while STAT1 was lower in imatinib-treated patients. It was demonstrated for the first time that there is a relation between the clinical outcome of CML patients and expression levels of JAK-STAT genes that could make this signaling pathway a new target for more effective treatment of CML.en_US
dc.publisherIzmir Institute of Technologyen_US
dc.subjectCancer patientsen_US
dc.subjectJAK/STAT genesen_US
dc.subjectChronic myeloid leukemiaen_US
dc.titleExpression levels of JAK/STAT signaling genes in newly diagnosed, drug sensitive and resistant chronic myeloid leukemia patientsen_US
dc.title.alternativeKronik miyeloid lösemi hastalarında JAK-STAT sinyal ileti yolağı genlerinin ekspresyon düzeyleri ve klinik seyire etkilerien_US
dc.typeMaster Thesisen_US
dc.institutionauthorKiraz, Yağmur-
dc.departmentThesis (Master)--İzmir Institute of Technology, Molecular Biology and Geneticsen_US
item.openairetypeMaster Thesis-
item.fulltextWith Fulltext- Department of Molecular Biology and Genetics-
Appears in Collections:Master Degree / Yüksek Lisans Tezleri
Files in This Item:
File Description SizeFormat 
T001316.pdfMasterThesis2.47 MBAdobe PDFThumbnail
Show simple item record

CORE Recommender

Page view(s)

checked on Apr 22, 2024


checked on Apr 22, 2024

Google ScholarTM


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.